NCT07183995

Brief Summary

The aim of this study will be to assess the association between GIT angiodysplasia with any hematological disorders as von Willebrand factor and Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
15mo left

Started Sep 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress36%
Sep 2025Aug 2027

Study Start

First participant enrolled

September 1, 2025

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

September 14, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 19, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2027

Last Updated

September 25, 2025

Status Verified

September 1, 2025

Enrollment Period

11 months

First QC Date

September 14, 2025

Last Update Submit

September 22, 2025

Conditions

GI Bleeding

Outcome Measures

Primary Outcomes (1)

  • Correlation between GIT Angiodysplasia and Hematological disorders

    All patients eligible to participate will undergo the following: 1. upper endoscopy 2. Colonoscopy 3. Complete blood count, CRP 4. D-Dimer, liver function tests, blood Urea and serum Creatinine 5. ECG 6. Coagulation profile (aPTT , von Willebrand factor activity \&antigen)

    Baseline

Secondary Outcomes (2)

  • Prevelance of different hematological disorders in angiodysplasia patients

    Baseline

  • Prognostic value of von Willebrand factor on patient's outcomes as risk of rebleeding and hospital mortality

    Baseline

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients eligible to participate will undergo the following: 1. upper endoscopy 2. Colonoscopy 3. Complete blood count, CRP 4. D-Dimer, liver function tests, blood Urea and serum Creatinine 5. ECG 6. Coagulation profile (aPTT , von Willebrand factor activity \&antigen)

You may qualify if:

  • Adults (above 18 years) and elderly Both genders Admitted to GIT Unit with manifestations of GIT bleeding diagnosed by upper endoscopy and Colonoscopy as angiodyplasia.

You may not qualify if:

  • other causes of GIT bleeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Gastrointestinal Hemorrhage

Condition Hierarchy (Ancestors)

Gastrointestinal DiseasesDigestive System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mennat-allah Alaa Abdelgaber

    Assiut University

    PRINCIPAL INVESTIGATOR

  • Mohamed Zein Elabdin Hafez

    Assiut University

    STUDY DIRECTOR

  • AbdelHamid Mohamed AbdelHamid

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Mennat-allah Alaa Abdelgaber, Resident

CONTACT

+201021789585Menna.17289695@med.aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigatir

Study Record Dates

First Submitted

September 14, 2025

First Posted

September 19, 2025

Study Start

September 1, 2025

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2027

Last Updated

September 25, 2025

Record last verified: 2025-09